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Background: Cellular therapy after organ transplantation is emerging as an intriguing strategy to achieve dose
reduction of classical immunosuppressive pharmacotherapy. Here, we introduce a new scoring system to assess
treatment-emergent adverse events (TEAEs) of adherent stem cell therapies in the clinical setting of allogeneic liver
transplantation (for example, the MiSOT-I trial Eudract CT: 2009-017795-25).
Methods: The score consists of three independent modalities (set of parameters) that focus on clinically relevant
events early after intravenous or intraportal stem cell infusion: pulmonary toxicity, intraportal-infusional toxicity and
systemic toxicity. For each modality, values between 0 (no TEAE) and 3 (severe TEAE) were defined. The score was
validated retrospectively on a cohort of n=187 recipients of liver allografts not receiving investigational cell therapy
between July 2004 and December 2010. These patients represent a control population for further trials. Score values
were calculated for days 1, 4, and 10 after liver transplantation.
Results: Grade 3 events were most commonly related to the pulmonary system (3.5% of study cohort on day 4).
Almost no systemic-related TEAEs were observed during the study period. The relative frequency of grade 3 events
never exceeded 5% over all modalities and time points. A subgroup analysis for grade 3 patients provided no
descriptors associated with severe TEAEs.
Conclusion: The MiSOT-I score provides an assessment tool to score specific adverse events that may occur after
adherent stem cell therapy in the clinical setting of organ transplantation and is thus a helpful tool to conduct a
safety study.
Keywords: Adherent adult stem cells, Mesenchymal stem cells, Multipotent adult progenitor cells, Solid organ
transplantation, Immunotherapy, Scoring adverse events, Phase I trialBackground
The results of solid organ transplantation as definitive
treatment for end-stage disease of the liver (for example,
cirrhosis and metabolic decompensation) and other
organs are clinically satisfactory [1]. However, the overall
success of organ transplantation as a curative therapy is
still hampered by the need for life-long immunosuppres-
sive treatment of the recipient to control graft rejection.* Correspondence: marc.dahlke@ukr.de
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reproduction in any medium, provided the orStandard-of-care immunosuppressive pharmacotherapy
has a variety of drug-specific unwanted effects, such as
the neurotoxicity of tacrolimus or the renal toxicity of
ciclosporin [2]. Moreover, immunosuppressants increase
the recipient’s risk of cancer [3] and opportunistic infec-
tions [4]. Immunomodulatory cellular therapy as an ad-
junct to classical pharmacotherapy has emerged as an
intriguing strategy to achieve dose reductions of im-
munosuppressive drug therapy.
Multipotent adult progenitor cells (MAPCs) are bone
marrow derived [5], adherent stem cells which are
closely related to mesenchymal stem cells (MSC) [6],al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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211 patients (= 67.2%)
exclusion criteria 3
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187 patients (59.6%)
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0 patients (= 0%)
187 patients included
criteria 1 = Patients who received a secondary
liver graft in the course of their follow up
criteria 2 = Age x > 65y ; x < 18y
criteria 3 = Living Donor
criteria 4 = HIV Positive
Figure 1 Study population and exclusion criteria. n=187 patients
are included out of an initial patient collective of n=314.
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tions in vitro and in vivo [7]. MAPCs and MSCs effect-
ively prolong allograft survival in small animal models
when combined with otherwise subtherapeutic doses of
suitable immunosuppressants, such as mycophenolate
[8,9]. Building on this body of preclinical evidence, we
have initiated a phase I study (MiSOT-I study, Eudract
CT no. 2009-017795-25) to apply MAPCs after allogeneic
liver transplantation (LTx) [10]. The primary endpoints
of the MiSOT-I study will be safety and feasibility of
MAPC infusions.
In the current paper, we introduce a scoring system
designed to evaluate treatment-emergent adverse events
(TEAEs) of intravenous and intraportal infusions of
MAPCs after liver transplantation. Since similar events
(mimicking ‘toxicity’) can also occur without cell therapy
in LTx recipients, we validated the score in 187 recipi-
ents of liver allografts not receiving investigational cell
therapy. We only focused on events that we anticipate to
be specific for adherent stem cell therapy in this clinical
setting. Hence, the current analysis outlines the back-
ground against which the toxicity of new cellular therap-
ies has to be evaluated. The future objective of cell
therapy after solid organ transplantation will be to estab-
lish the immunological efficacy of the cell product.
Therefore, we also used the current analysis to establish
a retrospective control group that will allow us to collect
first evidence of the immunological efficacy of MAPC
therapy after LTx.
Methods
Patients
One hundred and eighty-seven patients who had
received an allogeneic liver graft in our tertiary referral
center between July 2004 and December 2010 were
included in this retrospective analysis. Recipients of
living-related grafts, patients who received a secondary
liver graft during the entire course of their disease, HIV-
positive recipients, and patients older than 65 years or
younger than 18 years were excluded from the analysis
(Figure 1). We have obtained ethical approval for this
retrospective analysis from the local ethics committee
(Ethikkommission der Universität Regensburg, No. 10-
101-0244). Since patients data were analyzed in a
pseudonymous fashion only, no informed consent
was requested.
Data collection
All patients included were reviewed using a standardized
score sheet that will also be part of the MiSOT-I case re-
port form (Figure 2). Clinical information from the
Eurotransplant online database was also included. Add-
itionally, the time to the last rejection-free follow-up was
recorded as an indicator for the efficacy of standard-of-care immunosuppression. All data collected were stored
and computed using IBM SPSS 18.0 Statistics Software
(SPSS, Chicago, IL, USA). Data consistency was checked
by a secondary investigator (BF, MHD).Statistical methods
Data analysis was carried out by a biostatistician (FZ).
Proportions are presented as frequency counts and per-
centages, along with the corresponding 95% confidence
intervals (CI) following Wilson’s method [11]. Continu-
ous data are summarized as mean values and standard
deviations. For comparison of two groups, Pearson’s
chi-square test was applied for categorical variables and
the Mann–Whitney U-Test for continuous variables.
Rejection-free survival times were estimated by Kaplan-
Meier analysis, and distributions between groups were
compared by the log-rank test. All reported P values
are two-sided, and a P value of 0.05 was considered
the threshold of statistical significance. Hazard ratios
(HR) and corresponding 95% CI were calculated and
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Figure 2 Outline of the MiSOT-I score. Every modality is defined by a set of parameters. Each parameter amounts to the designated score. The
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No adjustment for multiple testing was performed.
MiSOT-I score
The MiSOT-I score was designed as a high-barrier score
that excludes clinical events that are clearly unacceptable
TEAEs in phase I/II development of adherent stem cellproducts in patients after liver transplantation. Based on
preclinical studies with adherent stem cell therapy
[12,13] and observations made in a variety of early trials
with adherent stem cells in indications other than solid
organ transplantation [14-16], we defined three inde-
pendent modalities (set of parameters) to reflect poten-
tially critical aspects of adherent stem cell therapy:
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tion), intraportal/infusional toxicity (first-pass after
intraportal infusion), and systemic toxicity (immune re-
action after cell infusion).
For each of the parameters of the MiSOT-I score,
values between 0 and 3 were defined (Figure 2). A score
of 0 implies no TEAE. Scores of 1 and 2 stand for inter-
mediate TEAEs, while a score of 3 indicates a clinically
unacceptable severe TEAE. In the prospective analysis of
the MiSOT-I trial, a score of 3 will be considered a
dose-limiting toxicity event.
Score values within a set of parameters were not
cumulated so that the maximum score in each set of
parameters defined the total score for that modality.
Thus, each patient received three independent scores.
To assess the clinical course of each patient, toxicity
scores were computed for day 1 (range of days, 0 to 1),
day 4 (range of days, 2 to 6), and day 10 (range of days,
8 to 12).
Pulmonary toxicity
Assessment of pulmonary toxicity was based on three
parameters, that is, the Horovitz Quotient (HQ) (FiO2/
PaO2), the postoperative weaning from mechanical ven-
tilation, and pulmonary embolism.
A HQ above 300 was defined as a score of 0, a HQ be-
tween 200 and 300 corresponded to a score of 1, and a
HQ below 200 triggered further assessment of a chest
X-ray for pulmonary infiltrations. Bilateral infiltrates as
assessed by a staff radiologist corresponded to a score of
3 (equivalent to an acute respiratory distress syndrome),
whereas the absence of such resulted in a score of 2
(equivalent to an acute lung injury) [17].
The course of postoperative weaning from mechanical
ventilation was assessed as follows: Successful extubation
without the need for reintubation within the first 48 h
was assigned a score of 0 [18,19]. Reintubation within 48
h after extubation was assigned a score of 2, and reintu-
bation more than 48 h after extubation within the first 5
postoperative days was assigned a score of 3.
The occurrence of CT-proven pulmonary emboli was
assessed in accordance with European consensus guide-
lines [20]. A positive finding was defined as a score of
3, whereas the constellation of elevated D-Dimers
(≥0.5 mg/L), dyspnea (tachypnea ≥20/min), tachycardia
(>100/min), and hypotonia (systolic blood pressure
<90 mmHg or a pressure drop of ≥40 mmHg for >15 min)
was assigned a score of 1.
Intraportal/infusional toxicity
The assessment of intraportal toxicity was based on hep-
atic duplex ultrasound results. The included parameters
were as follows: the maximum portal venous velocity
(PVV), the resistance index (RI) and systolic accelerationtime (SAT) of the hepatic artery, and finally the flow pat-
tern and patency of the hepatic vessels.
If the PVV was ≥15 cm/s a score of 0 was assigned. A
PVV between 0 cm/s and 15 cm/s resulted in a 2,
whereas a score of 3 was allocated in the case of portal
venous occlusion (if a surgical problem was excluded:
PVV = 0 cm/s, coherent post-stenotic flow acceleration,
and clinical judgment) [21,22].
If the RI ranged between 0.5 and 0.8 a score of 0 was
assigned. An RI above 0.8 but below 1 was given a score
of 1. A RI <0.5 together with a SAT below 0.08 s
resulted in a 2, whereas a score of 3 was allocated in the
case of hepatic arterial occlusion (if a surgical problem
was excluded: RI <0.5 together with a SAT ≥0.08 s [23],
vasospasm indicated by a RI ≥1 [24], and clinical
judgment).
Orthograde arterial blood flow and an open triphasic
flow pattern of the hepatic veins were given a score of 0.
Limited blood flow in the hepatic veins (monophasic or
biphasic flow pattern without surgical impairment) [25]
was assigned a score of 1. A score of 3 was allocated in
the case of retrograde arterial blood flow, or an occlu-
sion of the hepatic veins (>50% stenosis without a surgi-
cal problem). Although Doppler analysis is prone to
inter- and intra-observer error, it was considered the best
available tool for the assessment of hepatic perfusion
[26].
Systemic toxicity
The assessment of systemic toxicity was based on inten-
sive care unit and nursing records. Any clinical finding
implying an anaphylactic reaction was assigned a score
of 3. Shock was defined by the need for vasopressor
treatment or mechanical ventilation [27]. Any skin reac-
tion was assigned a score of 1. The absence of anaphyl-
axis or skin reactions corresponded to a score of 0. A
score value of 2 was not defined for this modality.
Rejection analysis
The future objective of cell therapy after solid organ
transplantation will be to establish the immunological
efficacy of the cell product. Therefore, we also used the
current analysis to determine the liver graft rejection-
free survival of the patients in our study cohort after
standard-of-care immunosuppressive treatment. These
data will serve as a retrospective control group allowing
us to collect any first evidence of the immunological effi-
cacy of our cell therapy protocol.
We compared the rejection-rates of patients who
received calcineurin inhibitors (ciclosporin A or tacroli-
mus) or sirolimus as their primary immusuppressive
regimen (group CNI) to the patients treated with CNI-
free immunosuppression (group CNI-free). We only
retrospectively analyzed primary immunosuppression
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changes to the immunosuppressive regimens were not
taken into account. Rejection-free survival time of liver
grafts was calculated from the date of graft implantation
to the date of acute graft rejection. We differentiated be-
tween the following observation periods: day 0 to 10;
day 0 to 30; day 0 to 90; day 0 to 365. Patients lost to
follow-up and patients who died during the observation
period were censored. For the primary rejection analysis,
only biopsy-proven acute graft rejections or death from
acute rejection were considered events. In a secondary
rejection analysis, cortisone pulse therapy during the
period on the intensive care unit was additionally con-
sidered an event for acute graft rejection.Results
Study cohort
A total of 314 patients from our institutional database
were included in this analysis (Figure 1). Patients who
required a secondary liver graft in the course of their
clinical follow-up were excluded from the study (52/314;
16.6%), as were children below the age of 18 years or
patients older than 65 years (51/314; 16.2%), and
patients who received a liver graft from a living donor
(24/314; 7.6%). A HIV-positive status was also con-
sidered an exclusion criterion, however there were no
HIV-positive patients among the initial 314 patients.
Ultimately, 187/314 (59.6%) patients were included in
the analysis; 72.7% of the study population were men.
The mean age was 50.6 years (Table 1).Modality analysis
All patients were reviewed using a standardized score
sheet (Figure 2). For the assessment of pulmonary tox-
icity, data for 187/187 patients (100%) were available on
day 1, 85/187 (45%) on day 4, and 41/187 (21.9%) on
day 10. For intraportal/infusional toxicity, data were
retrieved for 152/187 patients (81.3%) on day 1, 113/187
(60.4%) on day 4, and 77/187 (41.2%) on day 10. Finally,
for systemic toxicity, data were available for all patients
on days 1, 4, and 10. Table 2 shows the score distribu-
tion for each of the three modalities on days 1, 4, and
10. At all time points examined, the majority of analyzedTable 1 Baseline patient characteristics (n=187)
n %
Sex
Male 136 72.7
Female 51 27.3
Mean SD Minimum Maximum
Age (years) 50.64 9.78 19.75 64.92
Gender and age of the patient collective included (n=187).patients revealed no TEAEs. At no time did the fre-
quency of severe TEAEs (grade 3) exceed 5%.
Figure 3A illustrates the distribution of pulmonary
events. The highest relative frequency of grade 1 TEAEs
(15/41; 36.6%) was observed on day 10, whereas grade 2
and 3 TEAEs were most frequently seen on day 4
(15/85; 17.6% and 3/85; 3.5%, respectively). The distri-
bution of intraportal/infusional events is shown in
Figure 3B. Grade 1 and 3 TEAEs were most frequent
on day 1 (42/152; 27.6% and 3/152; 2%, respectively),
while grade 2 TEAEs occurred most often on day 10
(7/77; 9.1%). Finally, Figure 3C outlines the distribu-
tion of systemic events. Grade 1 TEAEs occurred in
1.1% of patients (2/187) on day 4 and 0.5% of patients
(1/187) on day 10. A grade 3 event occurred on only
one occasion, that is, on day 1 in one patient (0.5%).
All of the remaining patients revealed no systemic-
related TEAEs (186/187; 99.5% on days 1 and 10,
185/187; 98.9% on day 4).
Subgroup analysis for patients with grade 3 events
We further analyzed the subgroup of 12 patients who
developed clinically unacceptable severe TEAEs (grade 3
events) to identify clinical conditions typically associated
with such events. None of the 12 patients attained a
score of 3 in more than one modality. Moreover, no pa-
tient experienced grade 3 events on 2 different days
within a single modality. The following clinical events
were responsible for grade 3 TEAEs: one patient experi-
enced a pulmonary embolism on day 1; two patients
were reintubated within the first 5 postoperative days
after an extubation period >48 h; three patients devel-
oped acute respiratory distress syndrome on day 1 and
one on day 4; one patient had a portal venous occlusion
on day 1; two patients experienced a hepatic arterial oc-
clusion on day 1; one patient suffered an occlusion of
the hepatic veins on day 10, and one patient had an ana-
phylactic shock on day 1. To determine which patient
characteristics are associated with severe TEAEs and to
develop hypotheses for the early detection of these
patients, the group of 12 patients with grade 3 TEAEs
was compared with the remaining 175 patients. How-
ever, none of the parameters analyzed revealed a signifi-
cant difference between the two groups (Table 3).
Rejection-free survival
For the assessment of the liver graft rejection-free sur-
vival, data were available for 185/187 patients (98.9%).
One patient died prior to first immunosuppressive treat-
ment. For the other patient, it was not possible to accur-
ately determine the primary immunosuppression after
LTx retrospectively. As secondary changes to the im-
munosuppressive regimen and special patient character-
istics (for example, renal failure, high MELD scores)
Table 2 Score distribution
Modality Score Day 1 Day 4 Day 10
n % (95% CI) n % (95% CI) n % (95% CI)
Pulmonary Total n 187 85 41
0 91 65.9 (57.7-73.3) 47 55.3 (44.7-65.4) 22 53.7 (38.7-67.9)
1 31 22.5 (16.3-30.1) 20 23.5 (15.8-33.6) 15 36.6 (23.6-51.9)
2 12 8.7 (5.0-14.6) 15 17.6 (11.0-27.1) 4 9.8 (3.9-22.5)
3 4 2.9 (1.1-7.21) 3 3.5 (1.2-9.9) 0 0.0 (0.0-8.6)
Intraportal/Infusional Total n 152 113 77
0 98 64.5 (56.6-71.6) 82 72.6 (63.7-79.9) 59 76.6 (66.0-84.7)
1 42 27.6 (21.1-35.2) 25 22.1 (15.5-30.6) 10 13.0 (7.2-22.3)
2 9 5.9 (3.1-10.9) 6 5.3 (2.5-11.1) 7 9.1 (4.5-17.6)
3 3 2.0 (0.07-5.6) 0 0.0 (0.0-3.3) 1 1.3 (0.2-7.0)
Systemic Total n 187 187 187
0 186 99.5 (97.0-99.9) 185 98.9 (96.2-99.7) 186 99.5 (97.0-99.9)
1 0 0.0 (0.0-2.0) 2 1.1 (0.29-3.82) 1 0.5 (0.09-2.97)
3 1 0.5 (0.09-2.97) 0 0.0 (0.0-2.0) 0 0.0 (0.0-2.0)
Relative frequency of each score value within the three independent modalities.
CI, Confidence interval.
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not be considered to have prospective impact. However,
as a best available retrospective group, these data will be
valuable to establish any first efficacy of MAPC therapy.
Among the 129 patients of the CNI group, 94 (72.9%)
did not reject their grafts (biopsy-proven) and were thus
rejection-free during a follow-up period of 365 days.
Fifty-six patients were treated with CNI-free immuno-
suppression. These patients were mainly patients withA
C
0
0 0
0 0 0
1 1
1
1 1 1
2
2
2
3 3 3
3 3 3
Figure 3 Score distribution. The relative frequency of each score value w
above each bar indicates the respective score value.particularly high MELD scores and pronounced renal
impairment. Thirty-two of these patients (57.1%) did not
experience acute rejection during clinical follow-up
(HR=1.96, 95%CI: (1.17; 3.30), P=0.01). The total
rejection-free survival of all patients regardless of im-
munosuppressive treatment (also including the two
dropouts) was 67.4% (126/187) (Figure 4). In the early
postoperative phase until day 10, only 5/129 (3.9%) of
the CNI-treated patients rejected their liver graft,B
0
0 0
1 1
1
2 2 23 3 3
ithin the three independent modalities at days 1, 4, and 10. The value
Table 3 Score 3 risk factor profile
n Parameter n Score ≠ 3 n Score = 3 P
187 Gender (% male) 175 71.4 12 91.7 0.128
187 Age (years) 175 50.4 (SD 9.9) 12 53.8 (SD 8.4) 0.328
175 Cold ischemic period (Hours:Minutes) 164 10:09 (SD 2:19) 11 10:13 (SD 2:08) 0.417
183 Immunosuppression (% including CNI) 171 65,7 12 83.33 0.342
187 Blood type (% Type A) 175 45.7 12 58.3 0.397
187 Blood type (% Type B) 175 10.3 12 8.3 0.829
187 Blood type (% Type O) 175 35.4 12 33.3 0.883
187 Alcoholic liver cirrhosis as cause for LTx (%) 175 36.6 12 33.3 0.822
145 Last measured Gamma GT of donor (U/L) 137 55 (SD 54.7) 8 73.75 (SD 58.2) 0.343
148 Last measured Bilirubin (total) of donor (μmol/L) 140 9.59 (SD 11.3) 8 20.24 (SD 22.7) 0.211
135 Last measured alcalic phosphatase of donor (IU/L) 127 72.52 (SD 40.6) 8 73.63 (SD 27.6) 0.734
Statistical analysis of potential parameters correlating with the group of patients, who attained a score of 3 in one of the modalities.
SD, Standard deviation.
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(HR=2.41, 95%CI: (0.70; 8.32), P=0.17). A comparison
on day 30 (12.4% vs. 33.9%: HR=3.09, 95%CI: (1.59;
6.01), P <0.01) and day 90 (22.4% vs. 42.9%: (HR=2.36,
95%CI: (1.37; 4.06), P <0.01) emphasized the difference
between the two patient collectives.No. at risk 187 127 112 103
Cum. events 0 47 57 59 
Mean follow
Figure 4 Kaplan-Meier curve of rejection-free graft survival 365 days
graft rejection or patients who died due to an acute rejection were c
to follow-up were censored.Finally, a secondary retrospective rejection analysis
was performed that also considered the application of a
cortisone pulse therapy during the ICU period as an in-
dicator of suspected and treated acute graft rejection.
This analysis revealed an additional eight cases (six CNI
vs. two CNI-free) of non-biopsy-proven acute graft98 91 89 85
59 61 61 61
61 events
67.4% event-free
-up = 206.59 days
after liver transplantation patients with biopsy-proven acute
onsidered events. Patients who died of other causes and patients lost
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of an acute liver graft rejection. All of these events oc-
curred within the first 30 postoperative days, increasing
the rejection rate for the CNI group from 12.4%
(16/128) to 17.1% (22/129), and for the CNI-free group
from 33.9% (19/56) to 37.5% (21/55).
Discussion
The objective of this study was to retrospectively valid-
ate a newly designed scoring system for TEAEs of
liver-directed adherent stem cell therapy after liver
transplantation (Figure 2). This score will be used in an
approved phase-I study (MiSOT-I). The validation was
conducted retrospectively in a cohort of 187 recipients
of liver allografts who did not receive investigational cell
therapy.
The majority of the study population showed no
TEAEs (score 0) in accordance with the MiSOT-I score.
This was expected, because the cut-off values of the
score parameters were chosen to be a high barrier for
clearly unacceptable clinical events in the further devel-
opment of this and other stem cell therapies. For all mo-
dalities, the relative frequency of severe TEAEs (score 3)
did not exceed 5%. Previous studies looking at compar-
able complications after organ transplantation have
shown rates of pulmonary embolism or acute respiratory
distress syndrome of 0.37% [28] and 5.5% [29], respect-
ively. Also, portal venous occlusion, hepatic artery
thrombosis, and hepatic vein stenosis, which accounted
for most of the intraportal/infusional grade 3 TEAEs in
our cohort, have reported rates of up to 2.6%, 3.2%, and
1.5%, respectively [30,31].
By contrast, anaphylactic reactions (grade 3 parameter
for systemic toxicity) are extremely rare in the clinical
setting of solid organ transplantation, to our knowledge
only one such case has been described in the published
literature [32]. When comparing the three modalities,
the highest relative frequency of a score of 3 was most
often pulmonary-related (day 4 = 3.5%). This is consistent
with previous studies suggesting a high rate of pulmonary
complications following orthotopic liver transplant-
ation [29]. Systemic TEAEs were the least frequent, which
can be explained by the general low incidence of post-
operative anaphylaxis [32]. Thus, in view of the grade 3
events in our cohort, the results of this study confirm and
further quantify the findings in the literature concerning
pulmonary, hepatic, and systemic function after deceased-
donor liver transplantation.
A further subgroup analysis for patients with grade 3
events failed to provide a valuable hypothesis on which
descriptors are associated with severe TEAEs (Table 3).
Previous investigations have shown that patients with
alcoholic cirrhosis achieve the same postoperative sur-
vival and complication rates as non-alcohol-relatedtransplantations [33]. However, for all remaining para-
meters, numerous studies show that high age [34], male
gender [35], non-A blood type of the recipient [35], low
donor creatinine or bilirubine [36], a long cold ischemia
time [37], and a high MELD score [38] all significantly
correlate with an increased postoperative morbidity and
mortality rate after liver transplantation. Hence, a correl-
ation between grade 3 TEAEs and any of these parameters
was expected but was not established in our cohort. A
possible explanation for this discrepancy is the difference
in size of the two compared subgroups (n=12 vs. n=175),
although this was considered in the design of the statis-
tical analysis. Another reason for this observation may be
the choice of exclusion criteria (Figure 1), since most
previous comparative studies included re-transplanted
patients and patients above 65 years of age.
Biopsy-proven rejection-free survival after non-living
related orthotopic liver transplantation was analyzed.
Here, we grouped patients receiving CNI-free, sirolimus-
free, bottom-up immunosuppression (as will be used in
the MISOT-I study) against all other patients [39].
Patients who received ciclosporin A, tacrolimus, or siro-
limus as their primary immunosuppression presented
with a rejection-free graft survival rate of 72.9% after
365 days of follow-up (mean follow-up = 206.59 days).
The non-CNI, non-sirolimus, bottom-up group pre-
sented with rejection-free survival of 57.1% in compari-
son. Since time to biopsy-proven acute rejection will be
a secondary endpoint of the MiSOT-I trial, the analysis
of the rejection time in the present cohort can serve as a
retrospective comparator, naturally with all bias and
shortcomings of such an analysis.
Unavailability of data and low data consistency over
the analyzed time period was the key limitation of this
retrospective study. However, in the light of no other
available data, this study will still be the most valuable
comparator for MiSOT-I and other investigational phase
I studies applying adherent stem cell therapies. No
high-risk patients for the elected events could be
identified from our present cohort and, therefore, we
have no further means to exclude patient groups from
MiSOT-I.
Conclusion
Whether adherent stem cell therapy is indeed inherently
safe for all patients remains to be determined. In any
case, the current score appears suitable to identify pro-
blems of adherent stem cell infusions, at least in the
areas that we have included. Since the frequency of
grade 3 TEAEs in this retrospective analysis was never
higher than 5%, we may assume a probability of <5%
that complications that are identified by this score are
related to standard-of-care treatment after liver trans-
plantation. Consequently, in the clinical setting of the
Dillmann et al. Trials 2012, 13:211 Page 9 of 10
http://www.trialsjournal.com/content/13/1/211MiSOT-I study, in which we plan to administer MAPCs
to patients after liver transplantation, the probability of a
single event being stem-cell-related is greater than 95%
and the probability of two consecutive events being
stem-cell-related is greater than 99.75%. Therefore, two
grade 3 events have been defined as a stopping rule for
MiSOT-I.
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